Krytus D3 Tablet contains Vitamin D3 (Cholecalciferol) at a potency of 60,000 IU per tablet, designed to address and prevent Vitamin D deficiency in patients with inadequate endogenous synthesis or dietary intake. Vitamin D3 plays a crucial role in calcium and phosphorus homeostasis, promoting optimal bone mineralization and skeletal health. This high-dose formulation is typically prescribed for the treatment of conditions such as rickets, osteomalacia, hypoparathyroidism, and certain cases of osteoporosis where rapid correction of Vitamin D levels is required. Krytus D3 Tablet facilitates enhanced intestinal absorption of calcium, thereby improving bone density and reducing the risk of fractures. It may also be indicated in patients with chronic kidney disease or malabsorption syndromes where Vitamin D metabolism is impaired. Administration should be under medical supervision, with dosage tailored according to serum 25-hydroxyvitamin D levels and clinical response to avoid hypervitaminosis D, which can lead to hypercalcemia and associated complications. Regular monitoring of serum calcium and renal function is recommended during therapy. Krytus D3 Tablet is contraindicated in patients with hypercalcemia, Vitamin D toxicity, or hypersensitivity to cholecalciferol. It should be used cautiously in individuals with sarcoidosis or other granulomatous diseases.